Use: Labeled indications
- nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
- postoperative nausea and/or vomiting.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. (1.1) postoperative nausea and/or vomiting. (1.2) 1.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.
Ondansetron Injection is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.
In patients in whom nausea and/or vomiting must be avoided postoperatively, Ondansetron Injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic Ondansetron Injection and experience nausea and/or vomiting postoperatively, Ondansetron Injection may be given to prevent further episodes.
Ondansetron Injection is approved for patients aged 1 month and older.
Contraindications
4 CONTRAINDICATIONS Ondansetron Injection is contraindicated for patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. Anaphylactic reactions have been reported in patients taking ondansetron [see Adverse Reactions (6.2)]. The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.
- Patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. (4)
- Concomitant use of apomorphine. (4, 7.2)
Dosing: Adult
Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy (2.1):
- Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients.
- Adults and pediatric patients 6 months of age and older: The recommended dosage is 0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose), infused intravenously over 15 minutes.
- Administer the first dose 30 minutes before the start of chemotherapy and subsequent doses 4 and 8 hours after the first dose. Prevention of Postoperative Nausea and/or Vomiting (2.2):
- Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients.
- See full prescribing information for the recommended dosage and administration instructions for adult and pediatric patients 1 month of age and older. Patients With Severe Hepatic Impairment (2.3):
- Do not exceed a total daily dose of 8 mg.
2.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of…
2.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Chemotherapy Important Preparation Instructions
- Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients for the prevention of nausea and vomiting associated with emetogenic chemotherapy. For pediatric patients between 6 months and 1 year of age and/or 10 kg or less: Depending on the fluid needs of the patient, Ondansetron Injection may be diluted in 10 to 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection.
- Occasionally, ondansetron precipitates at the stopper/vial interface in vials stored upright. Potency and safety are not affected. If a precipitate is observed, resolubilize by shaking the vial vigorously.
- Do not mix Ondansetron Injection with solutions for which physical and chemical compatibility has not been established. In particular, this applies to alkaline solutions as a precipitate may form.
- Inspect the diluted Ondansetron Injection solution for particulate matter and discoloration before administration; discard if present.
- Storage: After dilution, do not use beyond 24 hours. Although Ondansetron Injection is chemically and physically stable when diluted as recommended, sterile precautions should be observed because diluents generally do not contain preservative.
- Compatibility: Ondansetron Injection is compatible and stable at room temperature under normal lighting conditions for 48 hours after dilution with the following intravenous fluids: 0.9% Sodium Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, and 3% Sodium Chloride Injection. Dosage and Administration The recommended dosage for adult and pediatric patients 6 months of age and older for prevention of nausea and vomiting associated with emetogenic chemotherapy is 0.15-mg/kg per dose for 3 doses (maximum of 16 mg per dose). Caution: Dilution of Ondansetron Injection is required in adult and pediatric patients prior to administration. Infuse intravenously over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy and then repeat 4 and 8 hours after the first dose.
2.2 Prevention of Postoperative Nausea
2.2 Prevention of Postoperative Nausea and/or Vomiting Important Preparation Instructions
- Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients.
- Inspect Ondansetron Injection visually for particulate matter and discoloration before administration; discard if present. Dosage and Administration The recommended dose and administration instructions for adult and pediatric patients 1 month of age and older for prevention of postoperative nausea and vomiting are shown in Table 1. Table 1. Recommended Dose and Administration of Ondansetron Injection for Prevention of Postoperative Nausea and/or Vomiting Population Recommended Single Dose Administration Instructions Timing of Administration Adults and pediatric patients older than 12 years of age 4 mg 1 May be administered intravenously or intramuscularly: Intravenously: infuse undiluted syringe contents (4 mg) over at least 30 seconds and preferably longer (over 2 to 5 minutes). Intramuscularly: inject undiluted syringe contents (4 mg) Administer immediately before induction of anesthesia, or postoperatively if the patient did not receive prophylactic antiemetics and experiences nausea and/or vomiting occurring within 2 hours after surgery 2,3 Pediatric patients 1 month to 12 years and more than 40 kg 4 mg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). Pediatric patients 1 month to 12 years and 40 kg or less 0.1 mg/kg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). 1. Few patients above 80 kg have been studied. 2. Administration of a second intravenous dose of 4 mg ondansetron postoperatively in adult patients who received a 4 mg prophylactic dose does not provide additional control of nausea and vomiting [see Clinical Studies (14.3)]. 3. For pediatric patients (1 month to 12 years) prevention of nausea and vomiting was only studied in patients who had not received prophylactic ondansetron.
2.3 Dosage Adjustment for Patients With Hepatic Impairment
2.3 Dosage Adjustment for Patients With Hepatic Impairment In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), a single maximal daily dose of 8 mg infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended. There is no experience beyond first-day administration of ondansetron in these patients [see Use in Specific Populations (8.6)].
Dosing: Altered kidney function
8.7 Renal Impairment Although plasma clearance is reduced in patients with severe renal impairment (creatinine clearance < 30 mL/min), no dosage adjustment is recommended [see Clinical Pharmacology (12.3)].
Patients with Renal Impairment: Due to the very small contribution (5%) of renal clearance to the overall clearance, renal impairment was not expected to significantly influence the total clearance of ondansetron. However, ondansetron mean plasma clearance was reduced by about 41% in patients with severe renal impairment (creatinine clearance < 30 mL/min). This reduction in clearance is variable and was not consistent with an increase in half-life [see Use in Specific Populations (8.7)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life [see Clinical Pharmacology (12.3)]. In such patients, a total daily dose of 8 mg should not be exceeded [see Dosage and Administration (2.3)].
2.3 Dosage Adjustment for Patients With Hepatic Impairment In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), a single maximal daily dose of 8 mg infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended. There is no experience beyond first-day administration of ondansetron in these patients [see Use in Specific Populations (8.6)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Little information is available about the use of ondansetron in pediatric surgical patients younger than 1 month [see Clinical Studies (14.2)]. Little information is available about the use of ondansetron in pediatric cancer patients younger than 6 months [see Clinical Studies (14.1), Dosage and Administration (2)].
The clearance of ondansetron in pediatric patients aged 1 month to 4 months is slower and the half-life is ~2.5-fold longer than patients who are aged > 4 to 24 months. As a precaution, it is recommended that patients younger than 4 months receiving this drug be closely monitored [see Clinical Pharmacology (12.3)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects enrolled in cancer chemotherapy-induced and postoperative nausea and vomiting US- and foreign-controlled clinical trials, 862 were aged 65 years and older. No overall differences in safety or effectiveness were observed between subjects 65 years and older and younger subjects.
A reduction in clearance and increase in elimination half-life were seen in patients older than 75 years compared with younger subjects [see Clinical Pharmacology (12.3)]. There were an insufficient number of patients older than 75 years of age and older in the clinical trials to permit safety or efficacy conclusions in this age-group.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dosage adjustment is not needed in patients over the age of 65.
Administration
2.2 Prevention of Postoperative Nausea and/or Vomiting Important Preparation Instructions • Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients. • Inspect Ondansetron Injection visually for particulate matter and discoloration before administration; discard if present. Dosage and Administration The recommended dose and administration instructions for adult and pediatric patients 1 month of age and older for prevention of postoperative nausea and vomiting are shown in Table 1. Table 1. Recommended Dose and Administration of Ondansetron Injection for Prevention of Postoperative Nausea and/or Vomiting Population Recommended Single Dose Administration Instructions Timing of Administration Adults and pediatric patients older than 12 years of age 4 mg 1 May be administered intravenously or intramuscularly: Intravenously: infuse undiluted syringe contents (4 mg) over at least 30 seconds and preferably longer (over 2 to 5 minutes). Intramuscularly: inject undiluted syringe contents (4 mg) Administer immediately before induction of anesthesia, or postoperatively if the patient did not receive prophylactic antiemetics and experiences nausea and/or vomiting occurring within 2 hours after surgery 2,3 Pediatric patients 1 month to 12 years and more than 40 kg 4 mg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). Pediatric patients 1 month to 12 years and 40 kg or less 0.1 mg/kg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). 1. Few patients above 80 kg have been studied. 2. Administration of a second intravenous dose of 4 mg ondansetron postoperatively in adult patients who received a 4 mg prophylactic dose does not provide additional control of nausea and vomiting [see Clinical Studies (14.3) ]. 3. For pediatric patients (1 month to 12 years) prevention of nausea and vomiting was only studied in patients who had not received prophylactic ondansetron.
US FDA labelDosage forms
Philippines
- ) solution for injection: 2 mg/mL (4 mg/2 mL, 2 mg/mL (8 mg/4 mL, 2 mg/mL (8 mg/4 mL) (4 mg/2 mL, 2 mg/mL(8 mg/4 mL, 250 mg/mL (500 mg/2 mL) (1 g/4 mL
- Solution for injection: 2 mg/mL, 4 mg/mL
- Film-coated tablet: 4 mg, 8 mg
- Oral solution: 4 mg/5 mL
- Orally disintegrating tablet: 8 mg
- Solution for intravenous injection: 2 mg/mL
- Syrup: 4 mg/5 mL
- Tablet: 8 mg
Registered products in the Philippines
71 products registered with the Food and Drug Administration (FDA) Philippines list Ondansetron as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products71
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AmnosetOndansetron | 2mg/ml Solution For Injection (IM/IV)4 mL USP Type I Clear and Colorless Glass Ampoule of 5's) | RxVAT-exempt | Bharat Parenterals LimitedIndia | Biocare Lifesciences Inc.Trader: AMN Life Science Pvt. Ltd. | DRP-4069 | Oct 19, 2027 | |
AsetronOndansetron (as hydrochloride) | 2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2 mL USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-4089-02 | Nov 8, 2027 | |
Beludan-2Ondansetron (as hydrochloride) | 2 mg/mL Solution For Injection (IM/IV)Type I clear glass ampoule x 1 mL (Box of 10's) | RxVAT-exempt | Hiral Labs LimitedIndia | Bellus Life Solutions, Inc. | DRP-12911 | Oct 25, 2027 | |
Beludan-4Ondansetron hydrochloride | 4 mg/mL Solution for Injection (I.M./I.V.)Type I clear glass ampoule x 1mL (Box of 10's) | RxVAT-exempt | Hiral Labs LimitedIndia | Bellus Life Solutions, Inc. | DRP-15883 | Sep 25, 2029 | |
DanasetOndansetron (as Hydrochloride) | 2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) (Box of 5’s) | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5894-04 | Dec 11, 2029 | |
EgezetOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 100's) | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Pharma 518, Inc.Importer: Ambica International Corporation | DRP-6106-01 | Apr 8, 2030 | |
EgezetOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Pharma 518, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609-04 | Apr 16, 2037 | |
EmistopOndansetron | 2 mg/mL Solution for Intravenous InjectionGlass ampoule in open tray x 4 mL (Box of 5's, 10's and 25's) | RxVAT-exempt | Baxter Pharmaceuticals India Private LimitedIndia | Macropharma CorporationImporter: Baxter Healthcare Philippines Inc. | DRP-6600 | Jul 8, 2030 | |
EmitronOndansetron (As Hydrochloride) | 2mg/mL (8mg/4mL) Solution For Injection (Im/Iv)USP Type I clear and colorless glass ampoule x 4 mL(Box of 5 's) and x 2 mL (Box of 10's) | RxVAT-exempt | Cisen Pharmaceutical Co., Ltd.China | ENDURE MEDICAL, INC. | DRP-7505 | Oct 15, 2031 | |
EmodanOndansetron (as hydrochloride) | 250 mg/mL (500 mg/2 mL) (1 g/4 mL) Solution for Injection (I.M./I.V.)USP Type I Colorless Glass Ampoule x 4 mL (Box of 5's) | RxVAT-exempt | Korea United Pharm. Inc.Korea | Qualimed Pharma Inc. | DR-XY29866 | Jul 4, 2030 | |
Enset-4Ondansetron (as hydrochloride dihydrate) | 4 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100 tablets) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-6608 | Mar 30, 2031 | |
ENSET-8Ondansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609 | Mar 30, 2037 | |
FrenvoOndansetron (as hydrochloride dihydrate) | 4 mg/5 mL Syrup0 mL capacity (50 mL net content) Ph. Eur. Type III glass bottle with white polypropylene/polyethylene cap and with a dosing device of 2.5 mL 5 mL double ended spoon (Box of 1's) | RxVAT-exempt | Delpharm Bladel B.V.Netherlands | Ambica International Corporation | DR-XY48494 | Nov 25, 2027 | |
KodasetronOndansetron (as hydrochloride dihydrate) | 2 mg/mL Solution for Injection (I.V./I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's) | RxVAT-exempt | Pt. Novell Pharmaceutical LaboaratoriesIndonesia | Kodapharm Med Corp.Importer: Accesspoint International Trading Inc. | DRP-13194-02 | Dec 22, 2027 | |
NausanOndansetron (as Hydrochloride) | 2 mg/mL (4 mg / 2 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 2 mL (Box of 5's). | RxVAT-exempt | Swiss Parenterals Ltd. (Block-B)India | Despina Pharma Inc. | DRP-13339 | Feb 1, 2028 | |
NauventOndansetron (as hydrochloride) | 2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2mL USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-4089-03 | Nov 8, 2027 | |
NauzexOndansetron (as hydrochloride) | 2 mg/mL (8 mg/4 mL) Solution for Injection (IM/IV)Type I Amber Colored Glass Ampoule x 5 mL (Net content: 4 mL) (Box of 1's) | RxVAT-exempt | Aroma İlaç San. Ltd. ŞtiTurkey | Importer: Medinova Pharmaceutical, Inc. | DRP-10891 | Dec 14, 2026 | |
NitronOndansetron Hydrochloride | 2 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 2 mL (Box of 5's) | RxVAT-exempt | Nitin Lifesciences Ltd.India | Seapharma International, Inc. | DRP-4945 | Nov 22, 2028 | |
NoneOndansetron (as hydrochloride dihydrate) | 2 mg / mL Solution for Injection (I.V/I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's) | RxVAT-exempt | PT. Novell Pharmaceutical LaboratoriesIndonesia | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-13194-03 | Dec 22, 2027 | |
NuovomedOndansetron (as hydrochloride dihydrate) | 2mg/mL (8 mg/4 mL) Solution For Injection (IM/IV)5-mL capacity Type -I Clear Glass Ampoule in Plastic Tray x 4 mL (net content) (Box of 10's) | RxVAT-exempt | Skymap Pharmaceuticals Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-18759 | Sep 1, 2032 | |
Odanson-8Ondansetron | 8mg Orally Disintegrating TabletAlu/Alu Blister Pack x 10's (Box of 30's). | RxVAT-exempt | Unison Pharmaceuticals Pvt. Ltd.India | Macropharma Corporation | DRP-13430 | Feb 16, 2028 | |
OndacareOndansetron (as hydrochloride dihydrate) | 2 mg/mL Solution For Injection (IM/IV)Type I Clear Glass Ampoule in PVC Trya x 4 mL (Box of 10's) | RxVAT-exempt | Able Medical Company LimitedThailand | Euro-Care Products Philippines | DRP-18758 | Sep 1, 2031 | |
OndaneoOndansetron | 2mg/mL (4mg/2mL) Solution for Injection (IM/IV)LDPE Ampoule x 2 mL in Aluminum Pouch x 5's (Box of 10's) | RxVAT-exempt | Aculife Healthcare Private LimitedIndia | Blue Global (FZE) | DRP-18036 | Apr 28, 2032 | |
Ondansaph-8Ondansetron (As Hydrochloride) | 2mg/mL(8mg/4mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule in PVC Tray x 4 mL (Box of 5's, 10's and 25's) | RxVAT-exempt | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11549 | Mar 30, 2027 | |
OndaSaveOndansetron (as hydrochloride dihydrate) | 2 mg / mL Solution for Injection (I.V./I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's) | RxVAT-exempt | Pt. Novell Pharmaceutical LaboratoriesIndonesia | Savelink Pharma and Trading Co.Importer: Accesspoint International Trading, Inc. | DRP-13194-04 | Dec 22, 2027 | |
OndatrixOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609-01 | Apr 16, 2037 | |
OndavellOndansetron (as hydrochloride dihydrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.M./I.V.)4 mL Type I Clear and Colorless Glass Ampoule (Box of 5's in Clear PVC Tray) | RxVAT-exempt | PT Novell Pharmaceutical LaboratoriesIndonesia | PROSWEAL HEALTHCARE INC. | DR-XY43655 | Aug 22, 2029 | |
OndavellOndansetron (as hydrochloride dihydrate) | 2mg/mL (4mg/2mL) Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass ampoule (Box of 5's in clear PVC tray) | RxVAT-exempt | PT Novell Pharmaceutical LaboratoriesIndonesia | PROSWEAL HEALTHCARE INC. | DR-XY43611 | Aug 11, 2029 | |
OndavellOndansetron (as hydrochloride) | 4 mg Film-Coated TabletAluminum Foil Strip x 6 Tablets (Box of 12's) | RxVAT-exempt | PT Novell Pharmaceutical LaboratoriesIndonesia | PROSWEAL HEALTHCARE INC. | DR-XY43610 | Aug 11, 2029 | |
OndavellOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletBox 2 Aluminum Foil Strips x 6's | RxVAT-exempt | PT Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY45022 | Feb 2, 2031 | |
OndavidOndansetron (as hydrochloride) | 2 mg/mL Solution for Injection (IM/IV)Borosilicate Glass Ampoule in PVC tray x 2 mL (Box of 5's ); Borosilicate Glass Ampoule in PVC tray x 4 mL (Box of 5's) | RxVAT-exempt | Qilu Pharmaceutical, Co., Ltd.China | Hovid Inc.Trader: Hovid Bhd. | DR-XY46599 | Jun 14, 2029 | |
OndengetOndansetron (as Hydrochloride) | 2 mg/mL Solution for Injection (IM/IV)Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) (Box of 5’s) | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | 2MG IncorporatedImporter: Ambica International Corporation | DRP-5894-03 | Dec 11, 2029 | |
OndensOndansetron (as Hydrochloride) | 2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Colour Band x 5 mL (4 mL net volume) (Box of 5's) | RxVAT-exempt | Cadilla Pharmaceuticals Ltd.India | Detoxicare Phils., Inc.Importer: Ambica International Corporation | DRP-5894-06 | Dec 11, 2029 | |
OndensOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Detoxicare Phils., Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609-07 | Apr 16, 2037 | |
OnderoOndansetron (as hydrochloride dihydrate) | 2 mg/mL Solution for Injection (I.M./I.V.)2 mL-net content USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper and light blue aluminum seal with light blue PP flip-off cap (Box of 1's) | RxVAT-exempt | Aspiro Pharma LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-14802 | Jan 11, 2029 | |
OndiOndansetron (as hydrochloride) | 2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)Clear Glass Ampoule x 2 mL and 4 mL (Box of 10 's) | RxVAT-exempt | Sakar Healthcare Pvt. Ltd.India | Macropharma Corporation | DRP-10895 | Dec 14, 2031 | |
Onetic 8Ondansetron (As Hydrochloride Dihydrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.M./I.V.)Type I clear, colorless glass ampoule x 4 mL (Box of 5's) | RxVAT-exempt | PT Pratapa NirmalaIndonesia | Importer: Exa Life Care Pharma, Inc. | DRP-11994 | May 27, 2027 | |
Onetic® 4Ondansetron (as hydrochloride dihydrate) | 2 mg/mL (4 mg/2 mL) Solution For Injection (I.M./I.V.)Clear, Colorless Type I Borosilicate Glass Ampoule x 2mL (Box of 5's) | RxVAT-exempt | PT. Pratapa NirmalaIndonesia | Importer: Exa Life Care Pharma Inc. | DRP-11342 | Mar 4, 2027 | |
Onriv 8Ondansetron (as Hydrochloride) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 4 mL in a PVC plastic tray (Box of 5’s) | RxVAT-exempt | East African (India) OverseasIndia | Ambica International Corporation | DRP-18812 | Sep 16, 2031 | |
OnsetraOndansetron (as hydrochloride dihydrate) | 2 mg/mL (8 mg/4 mL) Solution For Injection (IM/IV)5 mL-capacity Clear Glass Ampoule x 4 mL net content in Plastic Tray (Box of 10's) | RxVAT-exempt | Hana Pharm. Co., Ltd.South Korea | JLT Pharma Inc. | DRP-18607 | Aug 5, 2031 | |
OnsetronOndansetron | 2 mg/mL Solution for InjectionUSP Type I Clear Glass Ampoule x 2 mL (Box of 1's); USP Type I Clear Glass Ampoule x 4 mL (Box of 1's) | RxVAT-exempt | Zee Laboratories LimitedIndia | Eon Pharmatek, Inc | DR-XY42391 | Jul 4, 2030 | |
OnsettOndansetron (as Hydrochloride) | 2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Colour Band x 2 mL (2 mL net volume) (Box of 5’s); Flint USP Type I Glass Ampoule with Blue Colour Band x 5 mL (4 mL net volume) (Box of 5’s) | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Caledan Pharma Corp.Importer: Ambica International Corporation | DRP-5894 | Dec 11, 2029 | |
Onsett 4Ondansetron (as hydrochloride dihydrate) | 4 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s and 100's) | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-6105 | Apr 8, 2030 | |
Onsett 8Ondansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 10’s; Alu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Genace Pharma DistributorImporter: Ambica International Corporation | DRP-6106 | Apr 8, 2030 | |
OnsiaOndansetron (As Hydrochloride Dihydrate) | 2 mg/mL (4 mg/2 mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 2 mL | RxVAT-exempt | Siam Bheasach Co., Ltd.Thailand | MG Prime Pharmaceutical, Inc.Importer: Atlantic Pharmaceuticals, Inc. | DR-XY42169 | Aug 11, 2031 | |
OnsiaOndansetron (as Hydrochloride Dihydrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V.)USP Type I Clear Glass Ampoule x 4 mL (Box of 5's) | RxVAT-exempt | SIAM BHEASACH CO., LTD.Thailand | MG PRIME PHARMACEUTICAL, INC.Importer: Atlantic Pharmaceuticals, Inc. | DR-XY42426 | Aug 16, 2028 | |
OnsiatabOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 10's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | MG Prime Pharmaceutical, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609-05 | Jul 31, 2037 | |
Onstal-ForteOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | SGS Healthcare Co.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609-02 | Apr 26, 2037 | |
OnTheGet 4Ondansetron (as hydrochloride dihydrate) | 2 mg/mL (4 mg/ 2 mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule in White Tray x 2 mL (Box of 5's) | RxVAT-exempt | Eva Pharma for Pharmaceuticals Appliances and MedicalEgypt | Getmeds Philippines Inc. | DRP-17961 | Apr 15, 2031 | |
OnzetOndansetron (as Hydrochloride Dihydrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (IM/IV)5 mL-Capacity, 4 mL-net content Type I Clear and Colorless Glass Ampoule (Box of 10's) | RxVAT-exempt | Taiwan Biotech Co., Ltd.China | The Cathay Drug Co., Inc. | DR-XY45574 | Aug 24, 2031 | |
OnzetOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 10's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609-03 | Apr 16, 2037 | |
OtronOndansetron (as Hydrochloride Dihydrate) | 2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Myungmoon Pharmaceutical Co., Ltd.Korea | Marcburg Philippines Inc. | DR-XY44009 | Dec 18, 2029 | |
OtronOndansetron (as hydrochloride dihydrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (IM/IV)USP Type I Glass Ampoule x 4 mL (Box of 10's) | RxVAT-exempt | Myungmoon Pharmaceutical Co., Ltd.Korea | Marcburg Philippines Inc. | DR-XY44675 | Feb 15, 2031 | |
OtrosiaOndansetron (as hydrochloride) | 2 mg/mL (8 mg/4 mL) Solution For Injection (Iv/Im)Type I clear glass ampoule x 4 mL (Box of 10’s) | RxVAT-exempt | Scott-Edil Pharmacia Ltd.,India | Despina Pharma Inc. | DRP-18034 | Apr 28, 2031 | |
PhiltronOndansetron (as hydrochloride dihydrate) | 2 mg/mL Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 2 mL in a plastic tray (Box of 5's) | RxVAT-exempt | Ratnaris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17555 | Jan 26, 2031 | |
RasetronOndansetron (as hydrochloride) | 2 mg/mL Solution for Injection (IM/IV)USP Type I clear glass ampoule x 2 mL and 4 mL (Box of 5's and 10's) | RxVAT-exempt | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Raquel Abbas Pharma Inc. | DRP-17848 | Mar 23, 2031 | |
SaphdosetronOndansetron (As Hydrochloride) | 2mg/ml (8mg/4ml) (4mg/2ml) Solution For Injection (IM/IV)Type I Clear Glass Ampoule in PVC Tray x 2 mL and 4 mL (Box of 5's, 10's and 25's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-12506 | Aug 22, 2027 | |
SavetronOndansetron (as Hydrochloride) | 2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Colour Band x 2 mL (2 mL net volume) (Box of 5's); Flint USP Type I Glass Ampoule with Blue Colour Band x 5 mL (4 mL net volume) (Box of 5's) | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Curasave PharmaImporter: Ambica International Corporation | DRP-5894-05 | Dec 11, 2029 | |
StrobonOndansetron (as hydrochloride dihydrate) | 4mg / 5 mL Oral SolutionType III amber glass bottle (with measuring cup) x 60 mL (box of 1's) | RxVAT-exempt | Limited Liability Company "Kusum Pharm"Ukraine | Kusum Healthcare Private Limited Branch Office | DR-XY48968 | Dec 28, 2028 | |
TrinsetronOndansetron (as Hydrochloride) | 2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) Box of 5’s | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Genace Pharma DistributorImporter: Ambica International Corporation | DRP-5894-01 | Dec 11, 2029 | |
TroysetronOndansetron (as hydrochloride) | 2mg/mL Solution for Injection (IM/IV)Type I Clear Flint Glass Ampoule with Yellow OPC and Ring x 2mL (Box of 5's) Type I Clear Flint Glass Ampoule with Pink OPC and Ring x 4mL (Box of 5's) | RxVAT-exempt | Troikaa Pharmaceuticals LimitedIndia | Troikaa Pharmaceuticals Philippines, Inc. | DRP-16319 | Feb 4, 2030 | |
VominoOndansetron (as hydrochloride) | 2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2ml USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Curasave PharmaImporter: Pharmakon Biotec Inc. | DRP-4089 | Nov 8, 2027 | |
VomistatOndansetron (as hydrochloride) | 2 mg / mL (8 mg / 4 mL) Solution for Injection (IM/IV)Type I Amber Colored Glass Ampoule x 5 mL (Net content: 4 mL) (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. StiTurkey | Macropharma CorporationImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San. Ve Tic. A.S. | DRP-10891-01 | Dec 14, 2026 | |
VomistopOndansetron (as hydrochloride dihydrate) | 2 mg / mL Solution for Injection (I.V/I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's) | RxVAT-exempt | PT. Novell Pharmaceutical LaboratoriesIndonesia | Euro-Care Products PhilippinesImporter: Accesspoint International Trading Inc. | DRP-13194-01 | Dec 22, 2027 | |
Vomiz 8Ondansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 10's and 100's) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Macropharma Corporation | DRP-7286 | Mar 6, 2031 | |
Z-TronOndansetron (as hydrochloride) | 2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2ml USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Genace Pharma DistributorImporter: Pharmakon Biotec Inc. | DRP-4089-01 | Nov 8, 2027 | |
ZetronOndansetron (as hydrochloride) | 8mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Corona Remedies Private LimitedIndia | Biocare Lifesciences, Inc. | DRP-12060 | Jun 7, 2027 | |
ZofranOndansetron (as Hydrochloride dihydrate) | 2 mg/mL Solution for Injection (I.M./I.V.)Clear Glass Ampoule x 2 mL (Box of 10's); Clear Glass Ampoule x 4 mL (Box of 8's) | RxVAT-exempt | Delpharm Boucherville Canada Inc.Canada | Importer: Sandoz Philippines Corporation | DR-XY13358 | Jul 21, 2030 | |
ZofranOndansetron (as hydrochloride dihydrate) | 8 mg TabletAlu/Alu Blister Pack x 5’s Box of 10's | RxVAT-exempt | Aspen Bad Oldesloe GmbHGermany | Importer: Novartis Healthcare Philippines, Inc. | DR-XY13371 | Oct 15, 2027 | |
ZukastopOndansetron (as Hydrochloride) | 2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Color Band x 2 mL (2 mL net volume) (Box of 5’s); Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) (Box of 5’s) | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Ellebasy Medicale Group Inc.Importer: Ambica International Corporation | DRP-5894-02 | Dec 11, 2029 | |
ZukastopOndansetron (as hydrochloride dihydrate) | 8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ellebasy Medicale Group Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6609-06 | Apr 26, 2037 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Ondansetron Injection, USP: 4 mg/2 mL clear, colorless, nonpyrogenic, sterile solution in a single-dose vial. Injection: 4 mg/2 mL single-dose vial. (3)
Warnings/Precautions
- Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and bronchospasm have been reported in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists. (5.1)
- QT Prolongation and Torsade de Pointes: QT prolongation occurs in a dose-dependent manner. Cases of Torsade de Pointes have been reported. Avoid Ondansetron Injection in patients with congenital long QT syndrome. (5.2)
- Serotonin Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor agonists alone but particularly with concomitant use of serotonergic drugs. (5.3)
- Myocardial Ischemia: Do not exceed the recommended infusion rate and monitor patients during and after administration. (2.1, 2.2, 5.4)
- Masking of Progressive Ileus and/or Gastric Distension Following Abdominal Surgery or Chemotherapy-Induced Nausea and Vomiting: Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. (5.5)
5.1 Hypersensitivity Reactions
5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists.
5.2 QT Prolongation
5.2 QT Prolongation Ondansetron prolongs the QT interval in a dose-dependent manner [see Clinical Pharmacology (12.2)]. In addition, postmarketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid Ondansetron Injection in patients with congenital long QT syndrome. Electrocardiogram (ECG) monitoring is recommended in patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or patients taking other medicinal products that lead to QT prolongation.
5.3 Serotonin Syndrome
5.3 Serotonin Syndrome The development of serotonin syndrome has been reported with 5-HT 3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).
Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of Ondansetron Injection alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT 3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).
Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Ondansetron Injection and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Ondansetron Injection is used concomitantly with other serotonergic drugs [see Drug Interactions (7.5), Overdosage (10)].
5.4 Myocardial Ischemia
5.4 Myocardial Ischemia Myocardial ischemia has been reported in patients treated with ondansetron. In some cases, predominantly during intravenous administration, the symptoms appeared immediately after administration but resolved with prompt treatment. Coronary artery spasm appears to be the most common underlying cause.
Therefore, do not exceed the recommended infusion rate of Ondansetron Injection and monitor patients for signs and symptoms of myocardial ischemia during and after administration [see Dosage and Administration (2.1, 2.2) and Adverse Reactions (6.2)].
5.5 Masking of Progressive Ileus and Gastric Distension
5.5 Masking of Progressive Ileus and Gastric Distension The use of Ondansetron Injection in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and gastric distension. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.
Ondansetron Injection is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction.
Drug interactions
7.1 Drugs Affecting Cytochrome P-450 Enzymes
7.1 Drugs Affecting Cytochrome P-450 Enzymes Ondansetron does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron [see Clinical Pharmacology (12.3)].
On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.
7.2 Apomorphine
7.2 Apomorphine Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with ondansetron is contraindicated [see Contraindications (4)].
7.3 Phenytoin, Carbamazepine, and Rifampin
7.3 Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs [see Clinical Pharmacology (12.3)].
7.4 Tramadol
7.4 Tramadol Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small trials indicate that concomitant use of ondansetron may result in reduced analgesic activity of tramadol. Patients on concomitant ondansetron self-administered tramadol more frequently in these trials, leading to an increased cumulative dose in patient-controlled administration of tramadol.
7.5 Serotonergic Drugs
7.5 Serotonergic Drugs Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT 3 receptor antagonists and other serotonergic drugs, including SSRIs and SNRIs [see Warnings and Precautions (5.3)].
7.6 Chemotherapy
7.6 Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. In a crossover trial in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate.
7.7 Temazepam
7.7 Temazepam The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.
7.8 Alfentanil and Atracurium
7.8 Alfentanil and Atracurium Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. Interactions with general or local anesthetics have not been studied.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In vitro metabolism studies have shown that ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4.
In terms of overall ondansetron turnover, CYP3A4 plays a predominant role while formation of the major in vivo metabolites is apparently mediated by CYP1A2.
The role of CYP2D6 in ondansetron in vivo metabolism is relatively minor.
The pharmacokinetics of intravenous ondansetron did not differ between subjects who were poor metabolizers of CYP2D6 and those who were extensive metabolizers of CYP2D6, further supporting the limited role of CYP2D6 in ondansetron disposition in vivo .
Drug Interaction Studies CYP 3A4 Inducers : Ondansetron elimination may be affected by cytochrome P-450 inducers.
In a pharmacokinetic trial of 16 epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin, a reduction in AUC, C max , and t ½ of ondansetron was observed.
These changes in ondansetron exposure with CYP3A4 inducers are not thought to be clinically relevant [see Drug Interactions (7.3) ] .
Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron [see Clinical Pharmacology (12.3) ] .
Adverse reactions
- The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] QT Prolongation [see Warnings and Precautions (5.2)] Serotonin Syndrome [see Warnings and Precautions (5.3)] Myocardial Ischemia [see Warnings and Precautions (5.4)] Masking of Progressive Ileus and Gastric Distension [see Warnings and Precautions (5.5)] Chemotherapy-Induced Nausea and Vomiting: · The most common adverse reactions (≥7%) in adults are diarrhea, headache, and fever. (6.1)
- Postoperative Nausea and Vomiting: · The most common adverse reaction (≥10%) which occurs at a higher frequency compared with placebo in adults is headache. (6.1)
- · The most common adverse reaction (≥2%) which occurs at a higher frequency compared with placebo in pediatric patients aged 1 to 24 months is diarrhea. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The following adverse reactions have been reported in clinical trials of adult patients treated with ondansetron, the active ingredient of intravenous Ondansetron Injection across a range of dosages.
A causal relationship to therapy with Ondansetron Injection was unclear in many cases. Chemotherapy-Induced Nausea and Vomiting Table 2. Adverse Reactions Reported in > 5% of Adult Patients Who Received Ondansetron at a Dosage of Three 0.15-mg/kg Doses Adverse Reaction Number of Adult Patients With Reaction Ondansetron Injection 0.15 mg/kg x 3 (n = 419) Metoclopramide (n = 156) Placebo (n = 34) Diarrhea 16% 44% 18% Headache 17% 7% 15% Fever 8% 5% 3% Cardiovascular: Rare cases of angina (chest pain), electrocardiographic alterations, hypotension, and tachycardia have been reported.
Gastrointestinal: Constipation has been reported in 11% of chemotherapy patients receiving multiday ondansetron. Hepatic: In comparative trials in cisplatin chemotherapy patients with normal baseline values of aspartate transaminase (AST) and alanine transaminase (ALT), these enzymes have been reported to exceed twice the upper limit of normal in approximately 5% of patients.
The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic hepatic disease did not occur. Integumentary: Rash has occurred in approximately 1% of patients receiving ondansetron.
Neurological: There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving Ondansetron Injection, and rare cases of grand mal seizure. Other: Rare cases of hypokalemia have been reported. Postoperative Nausea and/or Vomiting The adverse reactions in Table 3 have been reported in ≥ 2% of adults receiving ondansetron at a dosage of 4 mg intravenous over 2 to 5 minutes in clinical trials.
Table 3. Adverse Reactions Reported in ≥ 2% (and with greater frequency than the placebo group) of Adult Patients Receiving Ondansetron at a Dosage of 4 mg Intravenous Over 2 to 5 Minutes Adverse Reaction 1,2 Ondansetron Injection 4 mg Intravenous (n = 547) Placebo (n = 547) Headache 92 (17%) 77 (14%) Drowsiness/Sedation 44 (8%) 37 (7%) Injection-site reaction 21 (4%) 18 (3%) Fever 10 (2%) 6 (1%) Cold sensation 9 (2%) 8 (1%) Pruritus 9 (2%) 3 (< 1%) Paresthesia 9 (2%) 2 (< 1%) 1.
Adverse reactions: Rates of these reactions were not significantly different in the ondansetron and placebo groups. 2. Patients were receiving multiple concomitant perioperative and postoperative medications. Pediatric Use: Rates of adverse reactions were similar in both the ondansetron and placebo groups in pediatric patients receiving ondansetron (a single 0.1-mg/kg dose for pediatric patients weighing 40 kg or less, or 4 mg for pediatric patients weighing more than 40 kg) administered intravenously over at least 30 seconds.
Diarrhea was seen more frequently in patients taking Ondansetron Injection (2%) compared with placebo (< 1%) in the 1-month to 24-month age-group. These patients were receiving multiple concomitant perioperative and postoperative medications.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ondansetron. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron. Cardiovascular Arrhythmias (including ventricular and supraventricular tachycardia, premature ventricular contractions, and atrial fibrillation), bradycardia, electrocardiographic alterations (including second-degree heart block, QT/QTc interval prolongation, and ST segment depression), palpitations, and syncope.
Rarely and predominantly with intravenous ondansetron, transient ECG changes, including QT/QTc interval prolongation have been reported [see Warnings and Precautions (5.2)]. Myocardial ischemia was reported predominately with intravenous administration [see Warnings and Precautions (5.4)]. General Flushing: Rare cases of hypersensitivity reactions, sometimes severe (e.g., anaphylactic reactions, angioedema, bronchospasm, cardiopulmonary arrest, hypotension, laryngeal edema, laryngospasm, shock, shortness of breath, stridor) have also been reported.
A positive lymphocyte transformation test to ondansetron has been reported, which suggests immunologic sensitivity to ondansetron. Hepatobiliary Liver enzyme abnormalities have been reported. Liver failure and death have been reported in patients with cancer receiving concurrent medications, including potentially hepatotoxic cytotoxic chemotherapy and antibiotics.
Local Reactions Pain, redness, and burning at site of injection. Lower Respiratory Hiccups. Neurological Oculogyric crisis, appearing alone, as well as with other dystonic reactions. Transient dizziness during or shortly after intravenous infusion. Skin Urticaria, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Eye Disorders Cases of transient blindness, predominantly during intravenous administration, have been reported.
These cases of transient blindness were reported to resolve within a few minutes up to 48 hours. Transient blurred vision, in some cases associated with abnormalities of accommodation, has also been reported.
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction | Number of Adult Patients With Reaction | ||
| Ondansetron Injection 0.15 mg/kg x 3 (n = 419) | Metoclopramide (n = 156) | Placebo (n = 34) | |
| Diarrhea | 16% | 44% | 18% |
| Headache | 17% | 7% | 15% |
| Fever | 8% | 5% | 3% |
| Adverse Reaction1,2 | Ondansetron Injection 4 mg Intravenous (n = 547) | Placebo (n = 547) |
| Headache | 92 (17%) | 77 (14%) |
| Drowsiness/Sedation | 44 (8%) | 37 (7%) |
| Injection-site reaction | 21 (4%) | 18 (3%) |
| Fever | 10 (2%) | 6 (1%) |
| Cold sensation | 9 (2%) | 8 (1%) |
| Pruritus | 9 (2%) | 3 (< 1%) |
| Paresthesia | 9 (2%) | 2 (< 1%) |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Published epidemiological studies on the association between ondansetron use and major birth defects have reported inconsistent findings and have important methodological limitations that preclude conclusions about the safety of ondansetron use in pregnancy (see Data). Available postmarketing data have not identified a drug-associated risk of miscarriage or adverse maternal outcomes.
Reproductive studies in rats and rabbits did not show evidence of harm to the fetus when ondansetron was administered intravenously during organogenesis at approximately 3.6 and 2.9 times the maximum recommended human intravenous dose of 0.15 mg/kg given three times a day, based on body surface area (BSA), respectively (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, miscarriages, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Available data on ondansetron use in pregnant women from several published epidemiological studies preclude an assessment of a drug-associated risk of adverse fetal outcomes due to important methodological limitations, including the uncertainty of whether women who filled a prescription actually took the medication, the concomitant use of other medications or treatments, recall bias, and other unadjusted confounders.
Ondansetron exposure in utero has not been associated with overall major congenital malformations in aggregate analyses. One large retrospective cohort study examined 1970 women who received a prescription for ondansetron during pregnancy and reported no association between ondansetron exposure and major congenital malformations, miscarriage, stillbirth, preterm delivery, infants of low birth weight, or infants small for gestational age.
Two large retrospective cohort studies and one case-control study have assessed ondansetron exposure in the first trimester and risk of cardiovascular defects with inconsistent findings. Relative risks (RR) ranged from 0.97 (95% CI 0.86 to 1.10) to 1.62 (95% CI 1.04, 2.54). A subset analysis in one of the cohort studies observed that ondansetron was specifically associated with cardiac septal defects (RR 2.05, 95% CI 1.19, 3.28); however this association was not confirmed in other studies.
Several studies have assessed ondansetron and the risk of oral clefts with inconsistent findings. A retrospective cohort study of 1.8 million pregnancies in the US Medicaid Database showed an increased risk of oral clefts among 88,467 pregnancies in which oral ondansetron was prescribed in the first trimester (RR 1.24, 95% CI 1.03, 1.48), but no such association was reported with intravenous ondansetron in 23,866 pregnancies (RR 0.95, 95% CI 0.63, 1.43).
In the subgroup of women who received both forms of administration, the RR was 1.07 (95% CI 0.59, 1.93). Two case-control studies, using data from birth defects surveillance programs, reported conflicting associations between maternal use of ondansetron and isolated cleft palate (OR 1.6 [95% CI 1.1, 2.3] and 0.5 [95% CI 0.3, 1.0]).
It is unknown whether ondansetron exposure in utero in the cases of cleft palate occurred during the time of palate formation (the palate is formed between the 6th and 9th weeks of pregnancy). Animal Data In embryo-fetal development studies in rats and rabbits, pregnant animals received intravenous doses of ondansetron up to 10 mg/kg/day and 4 mg/kg/day, respectively, during the period of organogenesis.
With the exception of short periods of maternal weight loss and a slight increase in the incidence of early uterine deaths at the high dose level in rabbits, there were no significant effects of ondansetron on the maternal animals or the development of the offspring. At doses of 10 mg/kg/day in rats and 4 mg/kg/day in rabbits, the maternal exposure margin was approximately 3.6 and 2.9 times the maximum recommended human oral dose of 0.15 mg/kg given three times a day, respectively, based on BSA.
No intravenous pre- and post-natal developmental toxicity study was performed with ondansetron. In an oral pre- and post-natal development study pregnant rats received oral doses of ondansetron up to 15 mg/kg/day from Day 17 of pregnancy to litter Day 21. With the exception of a slight reduction in maternal body weight gain, there were no effects upon the pregnant rats and the pre- and postnatal development of their offspring, including reproductive performance of the mated F1 generation.
Mechanism of action
12.1 Mechanism of Action Ondansetron is a selective 5-HT 3 receptor antagonist. While ondansetron’s mechanism of action has not been fully characterized, it is not a dopamine-receptor antagonist.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. In another trial in 6 normal male volunteers, a 16 mg dose infused over 5 minutes showed no effect of the drug on cardiac output, heart rate, stroke volume, blood pressure, or ECG.
Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers. Ondansetron has no effect on plasma prolactin concentrations. In a gender balanced pharmacodynamic trial (n = 56), ondansetron 4 mg administered intravenously or intramuscularly was dynamically similar in the prevention of nausea and vomiting using the ipecacuanha model of emesis.
Cardiac Electrophysiology QTc interval prolongation was studied in a double-blind, single intravenous dose, placebo- and positive-controlled, crossover trial in 58 healthy subjects. The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline correction was 19.5 (21.8) ms and 5.6 (7.4) ms after 15-minute intravenous infusions of 32 mg and 8 mg Ondansetron Injection, respectively.
A significant exposure-response relationship was identified between ondansetron concentration and ΔΔQTcF. Using the established exposure-response relationship, 24 mg infused intravenously over 15 minutes had a mean predicted (95% upper prediction interval) ΔΔQTcF of 14.0 (16.3) ms. In contrast, 16 mg infused intravenously over 15 minutes using the same model had a mean predicted (95% upper prediction interval) ΔΔQTcF of 9.1 (11.2) ms.
In this study, the 8-mg dose infused over 15 minutes did not prolong the QT interval to any clinically relevant extent.
Pharmacokinetics
Pharmacokinetics in Normal Adult Volunteers Age-group (years) n Peak Plasma Concentration (ng/mL) Mean Elimination Half-life (h) Plasma Clearance (L/h/kg) 19-40 11 102 3.5 0.381 61-74 12 106 4.7 0.319 ≥ 75 11 170 5.5 0.262 Absorption A trial was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics of a single 4-mg dose administered as a 5-minute infusion compared with a single intramuscular injection.
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
Specific Populations Geriatric Patients : A reduction in clearance and increase in elimination half-life are seen in patients older than 75 years of age [see Use in Specific Populations (8.5) ] .
Pharmacokinetics in Pediatric Cancer Patients Aged 1 Month to 18 Years Subjects and Age-group N CL (L/h/kg) Vd ss (L/kg) t ½ (h) Geometric Mean Mean Pediatric Cancer Patients 4 to 18 years N = 21 0.599 1.9 2.8 Population PK Patients 1 1 month to 48 months N = 115 0.582 3.65 4.9 1.
Mean terminal half-life was slightly reduced in pediatric patients (range, 2.5 to 3 hours) in comparison with adults (range, 3 to 3.5 hours).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics In normal adult volunteers, the following mean pharmacokinetic data have been determined following a single 0.15-mg/kg intravenous dose. Table 4. Pharmacokinetics in Normal Adult Volunteers Age-group (years) n Peak Plasma Concentration (ng/mL) Mean Elimination Half-life (h) Plasma Clearance (L/h/kg) 19-40 11 102 3.5 0.381 61-74 12 106 4.7 0.319 ≥ 75 11 170 5.5 0.262 Absorption A trial was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics of a single 4-mg dose administered as a 5-minute infusion compared with a single intramuscular injection.
Systemic exposure as measured by mean area under curve (AUC) were equivalent, with values of 156 [95% CI: 136, 180] and 161 [95% CI: 137, 190] ng•h/mL for intravenous and intramuscular groups, respectively. Mean peak plasma concentrations were 42.9 [95% CI: 33.8, 54.4] ng/mL at 10 minutes after intravenous infusion and 31.9 [95% CI: 26.3, 38.6] ng/mL at 41 minutes after intramuscular injection.
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL. Circulating drug also distributes into erythrocytes. Elimination Metabolism: Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine.
The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron. The metabolites are observed in the urine.
In vitro metabolism studies have shown that ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 plays a predominant role while formation of the major in vivo metabolites is apparently mediated by CYP1A2. The role of CYP2D6 in ondansetron in vivo metabolism is relatively minor.
The pharmacokinetics of intravenous ondansetron did not differ between subjects who were poor metabolizers of CYP2D6 and those who were extensive metabolizers of CYP2D6, further supporting the limited role of CYP2D6 in ondansetron disposition in vivo. Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
In a dose-proportionality trial, systemic exposure to 32 mg of ondansetron was not proportional to dose as measured by comparing dose-normalized AUC values with an 8-mg dose. This is consistent with a small decrease in systemic clearance with increasing plasma concentrations. Specific Populations Geriatric Patients: A reduction in clearance and increase in elimination half-life are seen in patients older than 75 years of age [see Use in Specific Populations (8.5)].
Pediatric Patients: Pharmacokinetic samples were collected from 74 cancer patients aged 6 to 48 months, who received a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses during a safety and efficacy trial. These data were combined with sequential pharmacokinetics data from 41 surgery patients aged 1 month to 24 months, who received a single dose of 0.1 mg/kg of intravenous ondansetron prior to surgery with general anesthesia, and a population pharmacokinetic analysis was performed on the combined data set.
The results of this analysis are included in Table 5 and are compared with the pharmacokinetic results in cancer patients aged 4 to 18 years. Table 5. Pharmacokinetics in Pediatric Cancer Patients Aged 1 Month to 18 Years Subjects and Age-group N CL (L/h/kg) Vd ss (L/kg) t ½ (h) Geometric Mean Mean Pediatric Cancer Patients 4 to 18 years N = 21 0.599 1.9 2.8 Population PK Patients 1 1 month to 48 months N = 115 0.582 3.65 4.9 1.
Population PK (Pharmacokinetic) Patients: 64% cancer patients and 36% surgery patients. Based on the population pharmacokinetic analysis, cancer patients aged 6 to 48 months who receive a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses would be expected to achieve a systemic exposure (AUC) consistent with the exposure achieved in previous pediatric trials in cancer patients (4 to 18 years) at similar doses.
In a trial of 21 pediatric patients (3 to 12 years) who were undergoing surgery requiring anesthesia for a duration of 45 minutes to 2 hours, a single intravenous dose of ondansetron, 2 mg (3 to 7 years) or 4 mg (8 to 12 years), was administered immediately prior to anesthesia induction. Mean weight-normalized clearance and volume of distribution values in these pediatric surgical patients were similar to those previously reported for young adults.
Mean terminal half-life was slightly reduced in pediatric patients (range, 2.5 to 3 hours) in comparison with adults (range, 3 to 3.5 hours). In a trial of 51 pediatric patients (aged 1 month to 24 months) who were undergoing surgery requiring general anesthesia, a single intravenous dose of ondansetron, 0.1 or 0.2 mg/kg, was administered prior to surgery.
As shown in Table 6, the 41 patients with pharmacokinetic data were divided into 2 groups, patients aged 1 month to 4 months and patients aged 5 to 24 months, and are compared with pediatric patients aged 3 to 12 years. Table 6. Pharmacokinetics in Pediatric Surgery Patients Aged 1 Month to 12 Years Subjects and Age-group N CL (L/h/kg) Vd ss (L/kg) t ½ (h) Geometric Mean Mean Pediatric Surgery Patients 3 to 12 years N = 21 0.439 1.65 2.9 Pediatric Surgery Patients 5 to 24 months N = 22 0.581 2.3 2.9 Pediatric Surgery Patients 1 month to 4 months N = 19 0.401 3.5 6.7 In general, surgical and cancer pediatric patients younger than 18 years tend to have a higher ondansetron clearance compared with adults leading to a shorter half-life in most pediatric patients.
In patients aged 1 month to 4 months, a longer half-life was observed due to the higher volume of distribution in this age-group. In a trial of 21 pediatric cancer patients (aged 4 to 18 years) who received three intravenous doses of 0.15 mg/kg of ondansetron at 4-hour intervals, patients older than 15 years exhibited ondansetron pharmacokinetic parameters similar to those of adults.
Patients with Renal Impairment: Due to the very small contribution (5%) of renal clearance to the overall clearance, renal impairment was not expected to significantly influence the total clearance of ondansetron. However, ondansetron mean plasma clearance was reduced by about 41% in patients with severe renal impairment (creatinine clearance < 30 mL/min).
This reduction in clearance is variable and was not consistent with an increase in half-life [see Use in Specific Populations (8.7)]. Patients with Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in those without hepatic impairment.
In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), clearance is reduced 2-fold to 3-fold and apparent volume of distribution is increased with a resultant increase in half-life to 20 hours [see Dosage and Administration (2.3), Use in Specific Populations (8.6)]. Drug Interaction Studies CYP 3A4 Inducers: Ondansetron elimination may be affected by cytochrome P-450 inducers.
In a pharmacokinetic trial of 16 epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin, a reduction in AUC, C max, and t ½ of ondansetron was observed. This resulted in a significant increase in the clearance of ondansetron. In a pharmacokinetic study of 10 healthy subjects receiving a single-dose intravenous dose of ondansetron 8 mg after 600 mg rifampin once daily for five days, the AUC and the t ½ of ondansetron were reduced by 48% and 46%, respectively.
These changes in ondansetron exposure with CYP3A4 inducers are not thought to be clinically relevant [see Drug Interactions (7.3)]. Chemotherapeutic Agents: Carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron [see Drug Interactions (7.6)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ondansetron (as Hydrochloride) 2 mg/mL, 2 mL Ampule | ₱129.00–₱155.45Reference ₱145.75 | per ampule | DPRI procurement range |
| Ondansetron (as Hydrochloride) 2 mg/mL, 4 mL Ampule | ₱68.78–₱275.00Reference ₱78.23 | per ampule | DPRI procurement range |
| Ondansetron (as Hydrochloride) 8 mg Tablet | ₱65.00–₱95.00Reference ₱67.50 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Ondansetron |
| PNF listing | Oral: 8 mg tablet (as hydrochloridedihydrate)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 2 mg/mL, 2 mL and 4 mL ampul (IM,IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ONDANSETRON · Sportpharm LLC [US FDA-approved label, version 1, July 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de72f1ec-75dd-4659-a1a0-32b28b72c799
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .